The estimated Net Worth of Andrea F Wainer is at least $13.4 Milion dollars as of 23 February 2024. Ms. Wainer owns over 12,500 units of Abbott Laboratories stock worth over $10,634,386 and over the last 5 years she sold ABT stock worth over $2,726,149. In addition, she makes $0 as Executive Vice President - Rapid and Molecular Diagnostics at Abbott Laboratories.
Sign up
Ms. Wainer ABT stock SEC Form 4 insiders trading
Andrea has made over 21 trades of the Abbott Laboratories stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 12,500 units of ABT stock worth $749,250 on 23 February 2024.
The largest trade she's ever made was exercising 42,500 units of Abbott Laboratories stock on 29 January 2024 worth over $2,159,000. On average, Andrea trades about 6,869 units every 55 days since 2019. As of 23 February 2024 she still owns at least 91,204 units of Abbott Laboratories stock.
You can see the complete history of Ms. Wainer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrea Wainer biography
Andrea Wainer serves as Executive Vice President - Rapid and Molecular Diagnostics of the Company. She serves as Vice President, Molecular Diagnostics from 2015 to 2019.
How old is Andrea Wainer?
Andrea Wainer is 51, she's been the Executive Vice President - Rapid and Molecular Diagnostics of Abbott Laboratories since 2019. There are 33 older and 9 younger executives at Abbott Laboratories. The oldest executive at Abbott Laboratories is Samuel Scott, 75, who is the Independent Director.
What's Andrea Wainer's mailing address?
Andrea's mailing address filed with the SEC is 100 ABBOTT PARK ROAD, , ABBOTT PARK, IL, 60064.
Insiders trading at Abbott Laboratories
Over the last 24 years, insiders at Abbott Laboratories have traded over $388,257,551 worth of Abbott Laboratories stock and bought 1,028,477 units worth $44,923,618 . The most active insiders traders include Miles D White, Richard A Gonzalez oraz Jeffrey M Leiden. On average, Abbott Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,003,344. The most recent stock trade was executed by John A. Jr. Mccoy on 1 September 2024, trading 27 units of ABT stock currently worth $3,100.
What does Abbott Laboratories do?
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States.
What does Abbott Laboratories's logo look like?
Complete history of Ms. Wainer stock trades at Abbott Laboratories
Abbott Laboratories executives and stock owners
Abbott Laboratories executives and other stock owners filed with the SEC include:
-
Miles White,
Executive Chairman of the Board -
Robert Ford,
President, Chief Executive Officer, Director -
Lisa Earnhardt,
Executive Vice President - Medical Devices -
Hubert Allen,
Executive Vice President, General Counsel, Secretary -
Miles D. White M.B.A.,
Exec. Chairman -
Daniel Salvadori,
Executive Vice President - Nutritional Products -
Robert B. Ford,
Chairman, Pres & CEO -
John Capek,
Executive Vice President - Ventures -
Robert E. Funck Jr.,
Exec. VP of Fin. & CFO -
Hubert L. Allen,
Exec. VP, Gen. Counsel & Sec. -
Daniel Gesua Sive Salvadori,
Exec. VP and Group Pres of Established Pharmaceuticals & Nutritional Products -
John F. Ginascol,
Exec. VP of Core Diagnostics -
Robert Alpern,
Independent Director -
Sally Blount,
Independent Director -
Glenn Tilton,
Independent Director -
Samuel Scott,
Independent Director -
William Osborn,
Lead Independent Director -
Roxanne Austin,
Independent Director -
Edward Liddy,
Independent Director -
Phebe Novakovic,
Independent Director -
Nancy McKinstry,
Independent Director -
Michelle Kumbier,
Independent Director -
John Stratton,
Independent Director -
Daniel Starks,
Independent Director -
Darren McDew,
Independent Director -
Randel Woodgrift,
Senior Vice President - CRM -
Alejandro Wellisch,
Senior Vice President - Established Pharmaceuticals, Latin America -
Jared Watkin,
Senior Vice President - Diabetes Care -
Christopher Scoggins,
Senior Vice President - Rapid Diagnostics -
Michael Pederson,
Senior Vice President - Electrophysiology and Heart Failure -
Joseph Manning,
Senior Vice President - Nutrition International -
Sammy Karam,
Senior Vice President - Established Pharmaceuticals, Emerging Markets -
Michael Dale,
Senior Vice President - Structural Heart -
Jaime Contreras,
Senior Vice President - Core Laboratory Diagnostics, Commercial Operations -
Charles Brynelsen,
Senior Vice President - Abbott Vascular -
Roger Bird,
Senior Vice President - U.S. Nutrition -
Andrea Wainer,
Executive Vice President - Rapid and Molecular Diagnostics -
Andrew Lane,
Executive Vice President - Established Pharmaceuticals -
John Ginascol,
Executive Vice President - Core Diagnostics -
Mary Moreland,
Executive Vice President of Human Resources -
Robert Funck,
Chief Financial Officer, Executive Vice President - Finance -
Gregory A. Ahlberg,
Sr. VP of Core Laboratory Diagnostics & Commercial Operations -
Elaine R. Leavenworth,
Sr. VP and Chief Marketing & External Affairs Officer -
Melissa Brotz,
VP of Public Affairs & Corp. Marketing -
James E. Young,
VP and Chief Ethics & Compliance Officer -
Scott Michael Leinenweber,
VP of Investor Relations, Licensing & Acquisitions -
Sean Shrimpton,
Senior Vice President -
Deepak S. Nath,
Senior Vice President -
Brian B Yoor,
Executive Vice President & CFO -
Brian J Blaser,
Senior Vice President -
Stephen R Fussell,
Senior Vice President -
Michael J Warmuth,
Senior Vice President -
Eric S Fain,
Senior Vice President -
Sharon J Bracken,
Senior Vice President -
Michael T Rousseau,
Pres., Cardiovasc. & Neuromod. -
Richard W Ashley,
Executive Vice President -
Christopher J. Calamari,
SENIOR VICE PRESIDENT -
Julie L. Tyler,
SENIOR VICE PRESIDENT -
Jean Yves Pavee,
Senior Vice President -
W James Farrell,
Director -
Thomas C Freyman,
Senior Vice President -
Georges H. De Vos,
Senior Vice President -
Katherine C. Doyle,
Senior Vice President -
J. Scott White,
Senior Vice President -
Charles D Foltz,
Senior Vice President -
Murthy V Simhambhatla,
Senior Vice President -
Thomas G Frinzi,
Senior Vice President -
John C Landgraf,
Senior Vice President -
Greg W Linder,
Vice President -
Heather L Mason,
Senior Vice President -
Paul K Magill,
Senior Vice President -
A. David Forrest,
Senior Vice President -
H Laurance Fuller,
Director -
Carlos Alban,
Senior Vice President -
James V Mazzo,
Senior Vice President -
Holger A Liepmann,
Senior Vice President -
William D Smithburg,
Director -
Laura J Schumacher,
Senior Vice President -
David Owen,
Director -
Edward L. Michael,
Senior Vice President -
Richard A Gonzalez,
Chief Operating Officer -
Donald V Jr Patton,
Senior Vice President -
William M Daley,
Director -
Robert B Hance,
Senior Vice President -
Mary T Szela,
Senior Vice President -
Roy S Roberts,
Director -
Corlis D Murray,
Senior Vice President -
Thomas F Chen,
Senior Vice President -
Olivier Bohuon,
Senior Vice President -
James L Tyree,
Senior Vice President -
W Ann Reynolds,
Director -
Boone Jr Powell,
Director -
Edward J Fiorentino,
Senior Vice President -
Gary E Mccullough,
Senior Vice President -
Jeffrey M Leiden,
President & COO -
Jack M Greenberg,
Director -
Joseph M Nemmers,
Senior Vice President -
John R Walter,
Director -
Jeffrey R Binder,
Senior Vice President -
William G Dempsey,
Senior Vice President -
A Barry Rand,
Director -
Thomas M Wascoe,
Senior Vice President -
Christopher B Begley,
Senior Vice President -
Lance B Wyatt,
Senior Vice President -
Guillermo A Herrera,
Senior Vice President -
Lasa Jose M De,
Senior Vice President -
Fernando Mateus,
SENIOR VICE PRESIDENT -
Gregory A Ahlberg,
SENIOR VICE PRESIDENT -
John A. Jr. Mccoy,
VICE PRESIDENT -
Philip P Boudreau,
EXECUTIVE VICE PRESIDENT -
Claire Babineaux Fontenot,
-
Michael O'grady,
-
Louis H. Morrone,
EXECUTIVE VICE PRESIDENT -
Patricia Paola Gonzalez,
-
Michael F Roman,